Jul 9, 2026 08:06AM
Jun 18, 2026 08:05AM
Jun 9, 2026 08:05AM
Jun 4, 2026 08:00AM
Jun 2, 2026 08:06AM
May 18, 2026 04:26PM
May 18, 2026 08:39AM Scienture reports 449% revenue growth in first quarter 2026
May 7, 2026 08:06AM
May 7, 2026 08:05AM
May 6, 2026 08:05AM
Apr 6, 2026 08:06AM
Mar 30, 2026 08:08AM
Mar 11, 2026 08:06AM
Feb 24, 2026 07:37AM Maxim Group Starts Scienture Holdings (SCNX) at Buy
Feb 3, 2026 08:06AM
Jan 14, 2026 08:06AM
Dec 22, 2025 08:05AM
Nov 13, 2025 04:38PM
Nov 4, 2025 08:05AM
Oct 23, 2025 08:05AM
Oct 13, 2025 08:00AM Wellgistics Health reappoints Prashant Patel as interim CEO
Oct 13, 2025 08:00AM
Oct 8, 2025 09:03AM
Sep 23, 2025 05:04PM
Sep 16, 2025 08:05AM
Aug 25, 2025 06:05AM
Jul 24, 2025 05:13PM
Jul 16, 2025 08:15AM Scienture Holdings regains NASDAQ listing compliance
Jun 17, 2025 08:05AM
May 22, 2025 08:20AM
Apr 8, 2025 08:06AM
Apr 3, 2025 08:26AM
Mar 25, 2025 08:05AM
Jan 30, 2025 06:09AM
Dec 10, 2024 08:06AM Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through
Dec 4, 2024 10:44AM

418,745 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All